Calcium-alpha-ketoglutarate supplement associated with 1.8-year lower biological age in 4,260-person cohort

Researchers led by Brian K. Kennedy analyzed 4,260 individuals who purchased saliva-based DNA epigenetic tests between 2020 and 2025 and completed detailed lifestyle and supplement questionnaires. Seventy-one percent of the cohort reported supplement use. Using a proprietary 9-CpG epigenetic clock with a mean absolute error of 5.4 years, the team evaluated 84 commonly used supplements. A commercially available delayed-release calcium-alpha-ketoglutarate (dAKG) plus vitamin supplement, identified as Rejuvant, was associated with an average 1.8-year lower Age Residual (the difference between biological and chronological age). This association held after adjusting for age, sex, smoking, health status, and additional covariates. Participants who reported taking regular AKG (not the delayed-release formulation) showed a much smaller, statistically insignificant benefit. Among medications, antihistamine use showed a non-significant trend toward benefit, limited by sample size. The study is cross-sectional, meaning it cannot prove causation: people who take supplements may differ from non-users in unmeasured ways. The 9-CpG clock is proprietary and less validated than established clocks like GrimAge or DunedinPACE.

A delayed-release calcium-alpha-ketoglutarate plus vitamin supplement was associated with 1.8-year lower Age Residual in a cross-sectional cohort of 4,260 health enthusiasts.